Skip to main content

Portfolio opens in a new window

AbbVie Ventures is focused on early-stage opportunities in immunology, oncology and neuroscience.

Active portfolio

opens in a new window Accent Therapeutics is leading the translation of RNA-modifying protein(RMP)biology into promising new precision therapies for cancer.
opens in a new window AM–Pharma is developing disease modifying Alkaline Phosphatase therapeutics.
opens in a new window ApoGen Biotechnologies is developing a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.
opens in a new window Aquinnah Pharmaceuticals is developing small molecule therapeutics targeting persistent stress granules for the treatment of neurodegenerative disease.
opens in a new window Artios Pharma is developing cancer treatments that target DNA Damage Response pathways to selectively kill cancer cells.
opens in a new window Capsida Therapeutics is creating a new class of targeted gene therapies for both CNS and non-CNS disorders.
opens in a new window Caraway Therapeutics is developing novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy.
opens in a new window Carisma Therapeutics is developing Chimeric Antigen Receptor-expressing macrophages to target and destroy solid tumors.
DG Medicines is employing a novel drug discovery platform to identify therapeutics for targeted protein degradation.
opens in a new window Disc Medicine is developing therapies addressing ineffective red blood cell production in hematologic diseases.
EndLyz Therapeutics is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias.
opens in a new window Enthera is developing first-in-class therapeutics for severe autoimmune disorders.
opens in a new window E-Scape Bio is developing therapeutics against genetic targets for neurodegenerative disease.
opens in a new window Faze Medicines is pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.
FireCyte is an emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.
opens in a new window Jnana Therapeutics is building the first drug discovery platform dedicated to the solute carrier family of transporters.
opens in a new window Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology.
opens in a new window Magnolia Neurosciences is developing potent and highly selective neuroprotective therapies.
opens in a new window Nitrase Therapeutics is developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases.
opens in a new window PACT is developing personalized adoptive cell therapies based on neoantigen-targeted T cells against cancer.
opens in a new window Palleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
opens in a new window Quanta Therapeutics is pioneering allosteric modulation to control RAS signaling for inhibition of the full scope of RAS-driven cancer types.
opens in a new window Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.
opens in a new window Ribon Therapeutics is discovering first-in-class small molecule inhibitors to block cancer cells' ability to survive under stress.
opens in a new window Stemson Therapeutics is developing a novel treatment for hair loss, using iPS cells to grow new Dermal Papilla and generate hair follicles de novo.
opens in a new window Tizona Therapeutics is an immunology company harnessing the power of the immune system to develop treatments for cancer.
opens in a new window Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.

Former investments

opens in a new window IPO, NASDAQ: ALEC
opens in a new window Acquired by Gilead
opens in a new window Acquired by CSL Behring
opens in a new window IPO, NASDAQ: CRBU
opens in a new window Merger with Aduro Biotech, NASDAQ: KDNY
Acquired by Lilly
opens in a new window Acquired by Locust Walk Acquisition Corp (SPAC merger), NASDAQ: EFTR
opens in a new window IPO, NASDAQ: XCUR
opens in a new window IPO, NASDAQ: KALA
opens in a new window Add: Acquired by Zymergen
opens in a new window IPO, NASDAQ: MORF
opens in a new window Acquired by Lilly
opens in a new window Acquired by Amgen
opens in a new window Acquired by Sanofi
opens in a new window Acquired by Gilead